Thanks phil,$EXEL news!
Exelixis to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 9
-- Presentation to be webcast on --
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s president and chief executive officer, will provide an overview of the company at the Morgan Stanley Global Healthcare Conference taking place September 8-10 in New York. The Exelixis presentation is scheduled for 11:45 a.m. EDT/8:45 a.m. PDT tomorrow, Tuesday, September 9, 2014.
The presentation will be webcast live and may be accessed via the Event Calendar page under Investors & Media at www.exelixis.com. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast.
About Exelixis
Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a highly selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis. For more information, please visit the company’s web site at www.exelixis.com.
Exelixis, the Exelixis logo, and COMETRIQ are registered U.S. trademarks.
Copyright Business Wire 2014
Source: Business Wire (September 8, 2014 - 4:05 PM EDT)
News by QuoteMedia
Exelixis to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 9
-- Presentation to be webcast on --
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s president and chief executive officer, will provide an overview of the company at the Morgan Stanley Global Healthcare Conference taking place September 8-10 in New York. The Exelixis presentation is scheduled for 11:45 a.m. EDT/8:45 a.m. PDT tomorrow, Tuesday, September 9, 2014.
The presentation will be webcast live and may be accessed via the Event Calendar page under Investors & Media at www.exelixis.com. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast.
About Exelixis
Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a highly selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis. For more information, please visit the company’s web site at www.exelixis.com.
Exelixis, the Exelixis logo, and COMETRIQ are registered U.S. trademarks.
Copyright Business Wire 2014
Source: Business Wire (September 8, 2014 - 4:05 PM EDT)
News by QuoteMedia
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
